Literature DB >> 19756785

Clonal spread of CC17 vancomycin-resistant Enterococcus faecium with multilocus sequence type 78 (ST78) and a novel ST444 in Taiwan.

Y-C Hsieh1, W-S Lee, T-Y Ou, P-R Hsueh.   

Abstract

From May 2007 to January 2008, 30 isolates of vancomycin-resistant enterococci (VRE), including 29 Enterococcus faecium (96.7%) and 1 E. faecalis (3.3%) were obtained from various clinical specimens of 30 patients treated at a university hospital in Taiwan. Among these patients, 27 had VRE infections, including urinary tract infection (n = 16), bacteremia (n = 5), wound infection (n = 5), and central nervous system infection (n = 1). Three patients had VRE colonization. All of these isolates belonged to the vanA genotype with vancomycin minimum inhibitory concentrations of 64>or=128 microg/ml. The isolate of E. faecalis had VanB phenotype-vanA genotype. All these isolates were susceptible to linezolid and were inhibited by tigecycline at 0.25 microg/ml. Multilocus sequence typing (MLST) analysis of the E. faecium isolates showed that 82.8% were ST78, which belongs to lineage C1. Transposon typing classified the 30 isolates of VRE into three types and most of the Tn1546-like elements contained an IS1251-like insertion sequence. Mating experiments showed that the vanA gene clusters were transferable at a frequency of about 10(-6) to 10(-7). Our findings indicate that nosocomial spread of VRE resulted from dissemination of lineage C1 E. faecium clones, including a novel E. faecium MLST type (ST444), and the horizontal transfer of Tn1546 elements among enterococci.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756785     DOI: 10.1007/s10096-009-0810-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

1.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Authors: 
Journal:  Am J Infect Control       Date:  2004-12       Impact factor: 2.918

2.  Vancomycin-resistant enterococci.

Authors:  A H Uttley; C H Collins; J Naidoo; R C George
Journal:  Lancet       Date:  1988 Jan 2-9       Impact factor: 79.321

3.  Diversity of VanA glycopeptide resistance elements in enterococci from humans and nonhuman sources.

Authors:  N Woodford; A M Adebiyi; M F Palepou; B D Cookson
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Role of horizontal transfer of the transposon Tn1546 in the nosocomial spread of vanA vancomycin-resistant enterococci at a tertiary care hospital in Korea.

Authors:  Soo Jin Yoo; Heungsup Sung; Young-Uk Cho; Mi-Na Kim; Chik Hyun Pai; Yang Soo Kim
Journal:  Infect Control Hosp Epidemiol       Date:  2006-08-31       Impact factor: 3.254

5.  Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from Korea.

Authors:  Kwan Soo Ko; Jin Yang Baek; Ji-Young Lee; Won Sup Oh; Kyong Ran Peck; Namyong Lee; Wee Gyo Lee; Kyungwon Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

6.  Typeability of Tn1546-like elements in vancomycin-resistant enterococci using long-range PCRs and specific analysis of polymorphic regions.

Authors:  G S Simonsen; M R Myhre; K H Dahl; O Olsvik; A Sundsfjord
Journal:  Microb Drug Resist       Date:  2000       Impact factor: 3.431

7.  Vancomycin-resistant enterococcus (VRE) carriage and infection in intensive care units.

Authors:  Kuo-Ming Yeh; L K Siu; Jen-Chang Chang; Feng-Yee Chang
Journal:  Microb Drug Resist       Date:  2004       Impact factor: 3.431

8.  Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147.

Authors:  M Arthur; C Molinas; F Depardieu; P Courvalin
Journal:  J Bacteriol       Date:  1993-01       Impact factor: 3.490

9.  Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents.

Authors:  Po-Ren Hsueh; Wen-Huei Chen; Lee-Jene Teng; Kwen-Tay Luh
Journal:  Int J Antimicrob Agents       Date:  2005-07       Impact factor: 5.283

10.  Epidemic and nonepidemic multidrug-resistant Enterococcus faecium.

Authors:  Helen L Leavis; Rob J L Willems; Janetta Top; Emile Spalburg; Ellen M Mascini; Ad C Fluit; Andy Hoepelman; Albert J de Neeling; Marc J M Bonten
Journal:  Emerg Infect Dis       Date:  2003-09       Impact factor: 6.883

View more
  17 in total

1.  Screening for vancomycin-resistant enterococci: an efficient and economical laboratory-developed test.

Authors:  H Fang; A-K Ohlsson; G-X Jiang; M Ullberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-06-10       Impact factor: 3.267

2.  Evaluation of species-specific PCR, Bruker MS, VITEK MS and the VITEK 2 system for the identification of clinical Enterococcus isolates.

Authors:  H Fang; A-K Ohlsson; M Ullberg; V Ozenci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-17       Impact factor: 3.267

Review 3.  Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance.

Authors:  Rob J L Willems; William P Hanage; Debra E Bessen; Edward J Feil
Journal:  FEMS Microbiol Rev       Date:  2011-07-04       Impact factor: 16.408

4.  Regional spread and control of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Kyoto, Japan.

Authors:  A Matsushima; S Takakura; M Yamamoto; Y Matsumura; M Shirano; M Nagao; Y Ito; Y Iinuma; T Shimizu; N Fujita; S Ichiyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-04       Impact factor: 3.267

5.  Molecular epidemiology of Enterococcus faecium isolates from an Italian hospital.

Authors:  L Fallico; C Boldrin; A Grossato; E Franchin; E De Canale; T Tommasini; S G Parisi; R Manganelli; G Palù
Journal:  Infection       Date:  2011-02-15       Impact factor: 3.553

6.  Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010.

Authors:  Hsih-Yeh Tsai; Chun-Hsing Liao; Yen-Hsu Chen; Po-Liang Lu; Cheng-Hua Huang; Chin-Te Lu; Yin-Ching Chuang; Shih-Ming Tsao; Yao-Shen Chen; Yung-Ching Liu; Wei-Yu Chen; Tsrang-Neng Jang; Hsiu-Chen Lin; Chih-Ming Chen; Zhi-Yuan Shi; Sung-Ching Pan; Jia-Ling Yang; Hsiang-Chi Kung; Chun-Eng Liu; Yu-Jen Cheng; Jien-Wei Liu; Wu Sun; Lih-Shinn Wang; Wen-Chien Ko; Kwok-Woon Yu; Ping-Cherng Chiang; Ming-Hsun Lee; Chun-Ming Lee; Gwo-Jong Hsu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

7.  Detection of an unusual van genotype in a vancomycin-resistant Enterococcus faecium hospital isolate.

Authors:  Jeanette W P Teo; Prabha Krishnan; Roland Jureen; Raymond T P Lin
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

8.  Genetic variability of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis isolates from humans, chickens, and pigs in Malaysia.

Authors:  Yitbarek Getachew; Latiffah Hassan; Zunita Zakaria; Saleha Abdul Aziz
Journal:  Appl Environ Microbiol       Date:  2013-05-10       Impact factor: 4.792

9.  Restricted gene flow among hospital subpopulations of Enterococcus faecium.

Authors:  Rob J L Willems; Janetta Top; Willem van Schaik; Helen Leavis; Marc Bonten; Jukka Sirén; William P Hanage; Jukka Corander
Journal:  mBio       Date:  2012-07-17       Impact factor: 7.867

10.  Hospital and community ampicillin-resistant Enterococcus faecium are evolutionarily closely linked but have diversified through niche adaptation.

Authors:  Marieke J A de Regt; Willem van Schaik; Miranda van Luit-Asbroek; Huberta A T Dekker; Engeline van Duijkeren; Catherina J M Koning; Marc J M Bonten; Rob J L Willems
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.